Educational Notice
Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Immune Modulation & Anti-Inflammatory Peptides
Immune modulation sits at the intersection of peptide research’s most clinically mature and most speculative work. Thymosin Alpha-1 is approved in 37 countries with a Phase II/III clinical record spanning decades. Larazotide completed Phase III trials for celiac disease. At the other end of this cluster, KPV and BPC-157 have meaningful preclinical anti-inflammatory data and no human trial evidence for immune-specific applications.
The mechanistic diversity here is notable: thymic peptides that restore T-cell competence, antimicrobial peptides that modulate the innate immune response at barrier sites, neuropeptides with systemic anti-inflammatory signaling, tight junction regulators that address gut barrier permeability, and broad cytoprotective peptides with secondary immune effects. These are not variations on a single immune theme.
Cluster at a Glance
8 compounds • 0 FDA-approved • 2 with Phase II/III data • 2 pilot/limited human data • 4 preclinical or crossover
Clinical Trials
Pilot / Human Data
Preclinical Only
How These Compounds Relate
The eight compounds in this cluster address immune function through four distinct mechanisms. Thymosin Alpha-1 and Thymalin restore adaptive immune competence by supporting thymic T-cell production—top-down immune restoration. LL-37 operates at the innate immune frontier, providing direct antimicrobial activity and calibrating the magnitude of the first-responder immune reaction. VIP suppresses systemic and mucosal inflammation through neuroimmune signaling. KPV, BPC-157, and TB-500 reduce cytokine-driven inflammatory damage at tissue sites—a downstream anti-inflammatory role rather than an upstream immune restoration role.
Larazotide is the outlier in this cluster mechanistically. It does not modulate immune cells directly—it targets the gut barrier to prevent the antigen translocation that triggers mucosal immune activation in the first place. The immune benefit is upstream and structural rather than cellular. This makes it uniquely relevant to conditions driven by gut permeability—celiac disease, IBD, and the broader “leaky gut” context—while being less relevant to systemic or infectious immune applications.
Thymosin Alpha-1 and Thymalin address the same fundamental problem—thymic involution and immune senescence—through different approaches. Thymosin Alpha-1 is a defined single peptide with a well-characterized mechanism and a strong clinical record. Thymalin is a complex extract from a research tradition with significant human data and significant provenance limitations. The two compounds are conceptually related but should not be treated as interchangeable in evidence terms.
BPC-157 and TB-500 appear here as crossovers because their anti-inflammatory cytokine data is real and well-documented in preclinical models, and community use for inflammatory conditions is extensive. The immune application is secondary to their primary tissue repair mechanisms. Neither compound has human immune data. Their tier placement in this cluster—Preclinical Only—reflects that honestly.